PIK3CA and hepatocellular carcinoma: Of note, synergistic effects of OTX008 with either Sorafenib or Everolimus have been reported in HCC cell lines before [79], which further substantiates the interaction of Gal‐1 with the PI3K‐AKT‐mTOR pathway.